JP2022526999A5 - - Google Patents
Info
- Publication number
- JP2022526999A5 JP2022526999A5 JP2021559442A JP2021559442A JP2022526999A5 JP 2022526999 A5 JP2022526999 A5 JP 2022526999A5 JP 2021559442 A JP2021559442 A JP 2021559442A JP 2021559442 A JP2021559442 A JP 2021559442A JP 2022526999 A5 JP2022526999 A5 JP 2022526999A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- chr1
- macular degeneration
- months
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025065469A JP2025108562A (ja) | 2019-04-08 | 2025-04-11 | 血漿カリクレイン阻害剤および眼障害におけるその使用方法 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962830802P | 2019-04-08 | 2019-04-08 | |
| US62/830,802 | 2019-04-08 | ||
| PCT/US2020/027287 WO2020210368A1 (en) | 2019-04-08 | 2020-04-08 | Plasma kallikrein inhibitors and methods of use thereof in ocular disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025065469A Division JP2025108562A (ja) | 2019-04-08 | 2025-04-11 | 血漿カリクレイン阻害剤および眼障害におけるその使用方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022526999A JP2022526999A (ja) | 2022-05-27 |
| JP2022526999A5 true JP2022526999A5 (https=) | 2023-04-12 |
| JP7668227B2 JP7668227B2 (ja) | 2025-04-24 |
Family
ID=72750647
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021559442A Active JP7668227B2 (ja) | 2019-04-08 | 2020-04-08 | 血漿カリクレイン阻害剤および眼障害におけるその使用方法 |
| JP2025065469A Pending JP2025108562A (ja) | 2019-04-08 | 2025-04-11 | 血漿カリクレイン阻害剤および眼障害におけるその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025065469A Pending JP2025108562A (ja) | 2019-04-08 | 2025-04-11 | 血漿カリクレイン阻害剤および眼障害におけるその使用方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US12589093B2 (https=) |
| EP (1) | EP3953395B1 (https=) |
| JP (2) | JP7668227B2 (https=) |
| AU (1) | AU2020273154A1 (https=) |
| CA (1) | CA3136326A1 (https=) |
| IL (1) | IL287066B1 (https=) |
| WO (1) | WO2020210368A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007104541A2 (en) * | 2006-03-16 | 2007-09-20 | Dyax Corp. | Compositions and methods using serine protease inhibiting peptides for treating ophthalmic disorders |
| MX373894B (es) * | 2012-11-08 | 2020-07-09 | Clearside Biomedical Inc | Métodos y dispositivos para el tratamiento de trastornos oculares en sujetos humanos. |
| CA2933900A1 (en) * | 2013-12-20 | 2015-06-25 | Georgia Tech Research Corporation | Formulations and methods for targeted ocular delivery of therapeutic agents |
| KR102736869B1 (ko) * | 2014-03-07 | 2024-12-02 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
| US10428158B2 (en) * | 2014-03-27 | 2019-10-01 | Dyax Corp. | Compositions and methods for treatment of diabetic macular edema |
| JP6824876B2 (ja) * | 2014-08-22 | 2021-02-03 | バイオクライスト ファーマシューティカルズ， インコーポレイテッド | アミジン誘導体組成物及びそれらの使用 |
| CA3041058A1 (en) | 2016-10-31 | 2018-05-03 | Biocryst Pharmaceuticals, Inc. | Carbamimidoylphenylcarbamoyl derivatives and pharmaceutical compositions thereof useful as kallikrein inhibithors |
| AU2018226872A1 (en) * | 2017-03-03 | 2019-09-05 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| JP2020528082A (ja) | 2017-07-17 | 2020-09-17 | ロイズマン，キース | 加齢黄斑変性と他の眼疾患の治療用の細胞透過性ペプチドを使用する治療薬の局所送達 |
-
2020
- 2020-04-08 EP EP20786941.3A patent/EP3953395B1/en active Active
- 2020-04-08 CA CA3136326A patent/CA3136326A1/en active Pending
- 2020-04-08 US US17/602,674 patent/US12589093B2/en active Active
- 2020-04-08 WO PCT/US2020/027287 patent/WO2020210368A1/en not_active Ceased
- 2020-04-08 JP JP2021559442A patent/JP7668227B2/ja active Active
- 2020-04-08 AU AU2020273154A patent/AU2020273154A1/en active Pending
-
2021
- 2021-10-07 IL IL287066A patent/IL287066B1/en unknown
-
2025
- 2025-04-11 JP JP2025065469A patent/JP2025108562A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20240207246A1 (en) | Pharmaceutical composition | |
| CN105307498B (zh) | 用于治疗眼病的组合物、制剂和方法 | |
| JP2022081661A5 (https=) | ||
| JP2023509336A5 (https=) | ||
| JP6872322B2 (ja) | クエン酸エステルを含有するデポ剤 | |
| US20110142923A1 (en) | Ophthalmic pharmaceutical compositions for the treatment of neoangiogenic pathologies of the eye | |
| US20060111388A1 (en) | Phenanthroline and derivatives thereof used to lower intraocular pressure in an affected eye | |
| JP2023506838A5 (https=) | ||
| JP2013510852A5 (https=) | ||
| JP2020533270A5 (https=) | ||
| KR102266014B1 (ko) | 안질환 예방 또는 치료용 점안 조성물 | |
| RU2011115499A (ru) | Применение модуляторов рецептора s1p в офтальмологии | |
| JP2022526999A5 (https=) | ||
| JP2021138710A5 (https=) | ||
| WO2005067891A1 (en) | Compositions comprosing memantine and polyanionic polymers for administration to the eye | |
| JP2019534269A5 (https=) | ||
| WO2019024433A1 (zh) | 氨基金刚烷胺单硝酸酯类化合物眼用组合物及其制剂和应用 | |
| FI4452260T3 (fi) | Aukkoliitoksen modulaattoreita ja niiden käyttö ikään liittyvän silmänpohjan rappeuman hoidossa | |
| JP2020530459A5 (https=) | ||
| JP4150846B2 (ja) | ステロイドを有効成分とする網脈絡膜疾患治療剤 | |
| US20250281472A1 (en) | Ophthalmic composition inhibiting occurrence of n-oxopyridine compound for preventing or treating eye disease | |
| CA2790407A1 (en) | Ophthalmic formulations | |
| TW201705953A (zh) | 用於治療眼疾的化合物 | |
| JP2025507416A5 (https=) | ||
| JPWO2012066994A1 (ja) | 神経保護作用を持つ薬剤配合 |